Amanda L. Brennan, Khin M. Gyi, David M

Slides:



Advertisements
Similar presentations
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Advertisements

Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation  Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger,
Monocyte chemoattractant chemokines in cystic fibrosis
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
Zachary M. Sellers, Lori McGlocklin, Andrea Brasch 
Anna L. P. Chapman, Brian M. Morrissey, Vihas T. Vasu, Maya M
HbA1c as a screening tool for cystic fibrosis related diabetes
Jodi E. Gustave, Joseph A. Jurcisek, Karen S. McCoy, Steven D
Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Pseudomonas aeruginosa in cystic fibrosis: Pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease  Malin Carlsson, Swati.
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Regional ventilation in cystic fibrosis measured by electrical impedance tomography  Zhanqi Zhao, Rainald Fischer, Inéz Frerichs, Ullrich Müller-Lisse,
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
John Widger, Sarath Ranganathan, Philip J. Robinson 
Renal impairment in children with cystic fibrosis
Baby bottle steam sterilizers disinfect home nebulizers inoculated with bacterial respiratory pathogens  Dana Towle, Deborah A. Callan, Patricia A. Farrel,
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population  Brandie D. Wagner, Frank J. Accurso,
Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J
Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations  Melanie Chin, Maya De Zoysa, Robert.
A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF  Christina Schjellerup Dalbøge, Tacjana.
Evaluation of salt supplementation in CF infants
Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients  J.L. Fothergill,
Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: A pilot study  I. Hammana, L. Coderre, S. Potvin, M. Costa,
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
Vitamin A and lung function in CF
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.
A.H. Gifford  Journal of Cystic Fibrosis 
Demographics of glucose metabolism in cystic fibrosis
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A
M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw 
Cystic fibrosis related diabetes in an extremely young patient
Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C
Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson 
Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function  Julia Seyfarth, Sutharsan Sivagurunathan,
Marie-Angela Schnyder, Christian Benden, Christoph Schmid 
Cytokine gene polymorphisms and severity of CF lung disease
Nasal polyposis in lung transplant recipients with cystic fibrosis
Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients  Marie-Claire Ishimo, Linda Belson, Sophie Ziai, Emile Levy, Yves.
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic  Amanda L. Griffiths, Danielle F. Wurzel,
Theresa A. Laguna, Cynthia B. Williams, Kyle R
Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale 
Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis  Joseph M. Collaco, Karen S. Raraigh, Lawrence.
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS  Dorota Sands, Ewa Sapiejka, Grzegorz.
Determining presence of lung disease in young children with cystic fibrosis: Lung clearance index, oxygen saturation and cough frequency  E.M. Bakker,
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,
Soluble inflammation markers in nasal lavage from CF patients and healthy controls  Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
Airway inflammation in mild cystic fibrosis
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation  Noa Nezer M. Sc, David Shoseyov, Eitan.
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa  C.E. Wainwright, A.L. Quittner, D.E.
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Robert P. Thomen, Laura L. Walkup, David J. Roach, Zackary I
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Presentation transcript:

Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis  Amanda L. Brennan, Khin M. Gyi, David M. Wood, Julie Johnson, Rick Holliman, Deborah L. Baines, Barbara J. Philips, Duncan M. Geddes, Margaret E. Hodson, Emma H. Baker  Journal of Cystic Fibrosis  Volume 6, Issue 2, Pages 101-109 (April 2007) DOI: 10.1016/j.jcf.2006.03.009 Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Comparison between blood and nasal glucose concentrations in cystic fibrosis patients. Nasal glucose measurements are shown for 40 people with cystic fibrosis who have a range of blood glucose concentrations. The line denotes a blood glucose concentration of 7.9 mmol L−1, the predicted airway glucose threshold [8]. Blood glucose was significantly correlated with nasal glucose (R=0.464, p=0.003). Journal of Cystic Fibrosis 2007 6, 101-109DOI: (10.1016/j.jcf.2006.03.009) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Representative 24-hour blood glucose profiles. Representative 24-hour glucose profiles from the middle monitored day are shown for A) a healthy volunteer, B) a person with cystic fibrosis and normal glucose tolerance and C) cystic fibrosis related diabetes. The bold line denotes sensor blood glucose values plotted against time. The dotted line denotes the predicted airway glucose threshold. Journal of Cystic Fibrosis 2007 6, 101-109DOI: (10.1016/j.jcf.2006.03.009) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Boxplot showing the proportion of the day spent by monitored groups with blood glucose above the airway glucose threshold (≥8 mmol L−1). The boxplot shows median, quartiles and extreme values (⁎) of the proportion of 24 h spent by each group with blood glucose above the airway glucose threshold. 10 subjects were studied in each group. One way analysis of variance demonstrated significant differences in the proportion of the day spent by each group with blood glucose above the threshold (p<0.0001). Post-hoc Bonferroni analysis showed that the proportion of the day spent with blood glucose above the airway threshold was significantly greater in CF-related diabetes than CF-normal glucose tolerance (p<0.0001) and healthy volunteers (p<0.0001) but was not significantly different between CF-normal glucose tolerance and healthy volunteers. Journal of Cystic Fibrosis 2007 6, 101-109DOI: (10.1016/j.jcf.2006.03.009) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Bar chart showing the effect of glucose concentration and time on bacterial growth. Bacterial growth quantified using optical density is shown for bacterial cultures at different time points and glucose concentrations: 0 mM □ 0.125 mM ▨ 0.25 mM 0.5 mM 1 mM 2 mM 4 mM 8 mM 10 mM ■. Journal of Cystic Fibrosis 2007 6, 101-109DOI: (10.1016/j.jcf.2006.03.009) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 5 Box plots of growth ratios for Staphylococcus aureus and Pseudomonas aeruginosa at different glucose concentrations compared to no added glucose after 24 and 48 h. Growth ratios were calculated by dividing OD620 measurements at 24 and 48 h for Staphylococcus aureus and Pseudomonas aeruginosa grown at each glucose concentration by OD620 for the same organism grown without glucose at each time point. Box plots indicate median, quartiles and extreme values (open circles) for OD620 ratios. ⁎p<0.05, ⁎⁎p<0.01, ⁎⁎⁎⁎p<0.0001 indicate significant differences in growth from control. Journal of Cystic Fibrosis 2007 6, 101-109DOI: (10.1016/j.jcf.2006.03.009) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions